Australia - Life Sciences Lawyers & Law Firms - Asia-Pacific - Chambers and Partners
Chambers & Partners has detected the use of an ad blocker.
We make use of tailor-made ads to enhance your experience of our website.
Please 'whitelist' https://www.chambersandpartners.com.
Close
Asia Guide

Life Sciences — Australia


Allens - Life Sciences

-

Band 1

第一等

Commentary from the Chambers Asia-Pacific guide

What the team is known for  A universally respected practice offering a comprehensive range of skills to the life sciences industries. Serves clients in the healthcare, pharmaceutical and biotech sectors as well as areas such as agriculture and food sciences. It is in high demand where multiple levels of expertise are required, from corporate, mergers, licensing and tax to regulatory regimes and competition issues. The firm is especially renowned for its robust approach to the protection and enforcement of IP rights.

Strengths  More than one client points to the firm's "overall excellent depth and breadth of knowledge across multiple practices."

Another client elaborates: "They always meet deadlines. I am also always confident that the advice is correct and that Allens has considered how that advice translates into the commercial and regulatory environment that we operate in."

Work highlights  Advised the global biotherapy group CSL on the divestment of one of its specialist businesses and the subsequent partnering with the preferred bidder.

Acted for Bristol-Myers Squibb and Otsuka Pharmaceutical in patent infringement proceedings against generic pharmaceutical companies that had attempted to have a generic version of its drug Abilify listed on the Schedule of Pharmaceutical Benefits. The matter included a High Court special leave application.

Notable practitioners

Jeremy Low, the practice head, focuses on domestic and international mergers, acquisitions and restructurings in the healthcare industries. His work includes assisting DuPont Pioneer on the restructuring and sale of its Australian agribusiness, Pioneer Australia Seeds, to New Zealand’s Philip Yates Family Holdings. A client reports that Low "provides outstanding support, legal advice and contract negotiating skills."

Sarah Matheson is considered by a peer to be "a fine practitioner" while a client comments: "I like interacting with her, and she is very good at managing clients, there are no surprises." She takes on patent protection and enforcement, regulatory, pricing and transactional matters for clients such as Gilead Sciences. She is acting for Gilead on a number of matters including challenging decisions of the Minister for Health in listing a new portfolio of its drugs on the Pharmaceutical Benefits Scheme incorrectly.

Andrew Wiseman is highly rated by a client because "he took time to understand the science and process in order to develop effective strategies to address the issues." He offers a blend of IP and transactional expertise in areas such as pharmaceuticals, medical devices and consumer and animal health. His busy practice includes assisting Merck Sharp & Dohme in successfully challenging a decision to refuse the grant of marketing authorisation in respect of the client's products for the treatment of insomnia.

Department profile by Allens

Department profile not yet provided by Allens. Please see their firm profile.

No Content Provided

Industries

  • {{industry.name}}

No Content Provided

Clients

  • {{client.name}}

No Content Provided

No Content Provided


Clayton Utz - Life Sciences

-

Band 1

第一等

Commentary from the Chambers Asia-Pacific guide

What the team is known for  A top choice for guiding clients through regulatory regimes in addition to offering a full suite of life sciences-focused expertise including patent protection, corporate and competition. Its impressive client roster includes global pharmaceutical, biotech, medical device and healthcare companies, as well as government agencies. Its expertise extends to product liability and privacy issues.

Strengths  One client sums up the group's attraction: "They have superb subject matter expertise, key understanding of the importance of the matter to us as the client, and they ensure that they understand our approach and alignment."

Another client reports: "They are the firm of choice when we are in a position of needing serious legal help in discussions with people like the regulators on therapeutic goods or trade mark disputes."

Work highlights  Advised Monsanto on the Australian aspects of its USD66 billion merger with Bayer, including competition clearances. The merged entity will be a global leader in agriculture, across various fields including the supply of seeds and traits, digital agriculture, and crop protection products.

Advised the Department of Health on a number of nationally significant projects including the procurement and establishment of a national cancer screening register. The advice covered IP rights, including those relating to new software and data storage, licensing and privacy issues.

Notable practitioners

Greg Williams, who heads the healthcare and life sciences group, combines a background in biochemistry with expertise in regulatory regimes, product liability and recalls, and related IP and competition matters. He advises government agencies and pharmaceutical companies. Recently this has included advising Medicines Australia on a range of administrative law rights and competition law obligations in connection with the listing of certain formulations for the treatment of rheumatoid arthritis on the Pharmaceutical Benefits Scheme. One client characterises him as "one of the best product liability and healthcare lawyers in Sydney," adding: "He foresees problems and has much business acumen. An absolutely key strength is that he can discuss legal problems with business sense and communicate it to management."

John Collins is well respected in the market for his "strong practice," particularly in connection with patent protection. He handles both advisory and contentious matters for an array of domestic and international pharma companies. Of late he acted for Orion Corporation in respect of patent infringement and revocation actions relating to the drug Stalevo which is used for the management of Parkinson's disease. The matter, valued at some AUD45 million, went to the Appeal Court and the case was made additionally complex as it involved a triple therapy product.

Department profile by Clayton Utz

Department profile not yet provided by Clayton Utz. Please see their firm profile.

No Content Provided

Industries

  • {{industry.name}}

No Content Provided

Clients

  • {{client.name}}

No Content Provided

No Content Provided


Herbert Smith Freehills - Life Sciences

-

Band 1

第一等

Commentary from the Chambers Asia-Pacific guide

What the team is known for  Excellence in the IP field and a go-to firm for high-stakes patent litigation, especially in relation to pharmaceuticals. Home to an outstanding depth of talent including patent attorneys and lawyers who are also qualified in sciences such as biochemistry, pharmacology and neuroscience. Also offers life science clients a full suite of expertise from M&A and finance to licensing, R&D agreements and regulatory issues.

Strengths  A source remarks that "they are a really great outfit - a great support team."

Work highlights  Acted for Becton Dickinson in an action against Braun in Australia, who it alleged made unjustifiable threats of patent infringement in respect of three of its Australian patents for IV catheters. Braun counterclaimed for patent infringement and the client further counterclaimed for invalidity of the three patents in issue. The action is one of a number of disputes affecting the client's IV catheter businesses in other jurisdictions.

Advised the Commonwealth Department of Finance in connection with the transfer of Australian Hearing into non-government ownership, a consortium headed by the Royal Institute for Deaf and Blind Children. The advice related to areas such as the establishment of an evaluation framework, the structure of the transaction, and potential competition issues.

Notable practitioners

Shaun McVicar is considered to be "an excellent manager of client relationships and is well respected on both pharma generic and originator-side cases." Another source confirms: "He has great rapport with clients and has great clients." He has handled a number of the highest-profile pharmaceutical cases including acting for Gilead in litigation relating to its blockbuster hepatitis C treatment which went to appeal.

Department profile by Herbert Smith Freehills

Department profile not yet provided by Herbert Smith Freehills. Please see their firm profile.

No Content Provided

Industries

  • {{industry.name}}

No Content Provided

Clients

  • {{client.name}}

No Content Provided

No Content Provided


MinterEllison - Life Sciences

-

Band 1

第一等

Commentary from the Chambers Asia-Pacific guide

What the team is known for  Offers an outstanding breadth of interdisciplinary skills that provide life science clients with an end-to-end service. As well as IP and regulatory know-how, clients can benefit from finance, venture capital, corporate and tax advice. Lawyers and patent attorneys possess an impressive range of technical and science qualifications, including those relating to cutting-edge biosciences, and assist clients ranging from start-ups and developing companies to multinational pharmaceutical and biotech organisations.

Strengths  One client reports: "I think their legal knowledge and strategic approach is excellent. They have very good scientific knowledge and they are very careful and responsive. And they're very good at adapting to your budget and requirements."

Another client remarks: "They are extremely flexible and helpful and they're not restrained by conflicts. Minters is my first port of call."

Work highlights  Advised Antisense Therapeutics on a global technology licensing deal for the development and commercialisation of an Antisense drug for the treatment of acromegaly. This AUD100 million matter involved complex licensing, corporate and IP issues.

Assisted Brandon Capital on the setting up of a life sciences fund through the existing Medical Research Commercialisation Fund as part of the new Biomedical Translation Fund valued at some AUD460 million. The initiative's goal is to enable Australian and New Zealand medical research organisations to lead in the commercialisation of medical discoveries.

Notable practitioners

Wayne McMaster is universally admired and liked not only for his adept handling of the protection of IP assets within the life sciences sector but also for his ability to bring together all the necessary talent from within the firm. One client observes: "He really understands life sciences and pharma businesses and so the advice is pragmatic and appropriate. You get the full package - full credit to Wayne that he has such a great team." Others make reference to his strategic approach and ability to "think ahead, see the bigger picture and boil things down into logical steps." He represented Ono Pharmaceutical and ER Squibb in a patent revocation action concerning what is thought to be the first substantive biologics patent case in Australia, which related to breakthrough PD-1 antibodies and their use in the treatment of cancer.

James Hutton has a focus on corporate advisory work within the life sciences industries including capital raisings and fund formations. An interviewee says of him: "James is very smart, commercial and pragmatic, a really good commercial lawyer. He understands the life sciences sector – I know his work is broader but he has sector expertise." Another adds: "He is a really nice guy, easy to get on with. It's been a really pleasant working relationship." He assisted Hexima, a public unlisted drug development company, on a fully underwritten rights issue to raise capital to progress clinical trials and to develop its plant defensin technology platform.

Department profile by MinterEllison

Department profile not yet provided by MinterEllison. Please see their firm profile.

No Content Provided

Industries

  • {{industry.name}}

No Content Provided

Clients

  • {{client.name}}

No Content Provided

No Content Provided


Baker McKenzie - Life Sciences

-

Band 2

第二等

Commentary from the Chambers Asia-Pacific guide

What the team is known for  Well-established reputation in the healthcare industry and especially in demand for its knowledge of global markets generally and Asia-Pacific in particular. Works with global pharma, medical device and healthcare corporates and offers a full suite of services from M&A and competition to IP, regulations and R&D matters. Active in providing Australian and regional clients with seminars on the latest legal, regulatory and technological developments.

Strengths  A client appreciates that the team is "very supportive and very pragmatic," adding: "I cannot overstate from an in-house point of view how important that is, and they can refer on to a network across the firm. Their jurisdictional knowledge is good too."

Another confirms: "They are solid, robust and have a very wide geographical reach. I have been impressed with the firm’s ability to connect different practice areas and global offices quickly and effectively."

Work highlights  Advised Allergan on the divestiture of its global generic pharmaceuticals business, Actavis Generics, to Teva Pharmaceutical. The transaction was worth around USD33.4 billion in cash and Teva stock valued at USD5.4 billion.

Advised the New South Wales Government Department of Family and Community Services in relation to Australian Unity's successful AUD114 million bid for the Home Care Service of New South Wales.

Notable practitioners

Benjamin McLaughlin is highlighted for "being good at leading the practice throughout APAC" and is considered "a very good guy who is extremely well connected and will go the extra mile for you." He is also considered by a client to be "a subject matter expert who adds the international flavour because he knows the other markets." He acted for IMS Health on the acquisition of 25% of healthcare data analyst NostraData and the establishment of a joint venture between IMS and NostraData.

Elisabeth White leads the healthcare group and specialises in IP and regulatory matters. Her clients include a number of major pharmaceutical and medical device companies, and interviewees credit her with the ability to "instil confidence," adding: "She is clearly an expert in her area of work and a pleasure to work with." Another confirms: "She is certainly well known within the pharma sector."

Department profile by Baker McKenzie

Department profile not yet provided by Baker McKenzie. Please see their firm profile.

No Content Provided

Industries

  • {{industry.name}}

No Content Provided

Clients

  • {{client.name}}

No Content Provided

No Content Provided


Corrs Chambers Westgarth - Life Sciences

-

Band 2

第二等

Commentary from the Chambers Asia-Pacific guide

What the team is known for  A well-established track record acting for life sciences clients, offering a comprehensive range of skills to global and local pharma, biotech and consumer product companies. Tackles both litigious and advisory work, including patent litigation, regulation, supply and pricing of medicines, complementary medicines, labelling and product recalls. Additionally assists clients on related corporate, structuring and M&A and tax issues.

Strengths  A client highlights the scope of the team's expertise: "They have a very good breadth in the practice and have been able to help with corporate law issues, real estate and trade marks, so they can cover whatever we need."

Work highlights  Acted for Merck Sharp & Dohme on the Australian leg of global litigation concerning the anti-PD1 antibody Keytruda. The product had received accelerated approvals in the treatment of cancers, and Merck challenged patents covering a competing anti-PD1 antibody.

Acted for US-based Cargill in an appeal brought by Meat & Livestock Australia regarding a patent covering a cattle genome. The case raised a number of important issues such as the patentability of genes.

Notable practitioners

Odette Gourley is widely acknowledged for her patent litigation skills, which are combined with advisory work regarding areas such as regulations, the reimbursement system and product liability. A client declares: "She is excellent, I cannot fault her; she's responsive, and gives comfort in her advice. I have worked with a lot of firms and she is my favourite." She counts well-known life sciences corporates among her clientele and is advising a number of them on the issues surrounding the cutting-edge biosimilars industry.

Kate Hay draws praise for being "particularly impressive as an IP litigator with a strong focus on the life sciences sector." A client elaborates that "she has good sector insight, understanding and knowledge both locally in Australia and across the Asia-Pacific region." Her broad practice includes advising Lundbeck on a range of matters including litigation with generic companies.

Department profile by Corrs Chambers Westgarth

Department profile not yet provided by Corrs Chambers Westgarth. Please see their firm profile.

No Content Provided

Industries

  • {{industry.name}}

No Content Provided

Clients

  • {{client.name}}

No Content Provided

No Content Provided


Norton Rose Fulbright - Life Sciences

-

Band 2

第二等

Commentary from the Chambers Asia-Pacific guide

What the team is known for  A dedicated group that is part of an extensive Asia-wide offering. Areas of specialism include corporate and M&A, product liability, IP, litigation and regulatory regimes, assisting clients on all facets of the commercialisation of products. Acts for global pharmaceutical corporates, healthcare and personal product companies.

Strengths  A client sums up the attraction of the team: "The quality of work, value for money and service make you feel like a valued client."

Another client adds: "There is no over-servicing, they are not afraid to give advice off the cuff, it's commercially relevant - they are really great to work with."

Work highlights  Acted for Smith & Nephew's Australian subsidiary in defence of a medical device class action. The class action proceedings were commenced in the Federal Court following a recall of an orthopaedic knee device. The firm also handled the litigation for the US parent company.

Advised a major manufacturer and distributor of nutraceuticals on a trade sale and licensing that threw up a range of regulatory matters on goods that were regulated by the Therapeutic Goods Administration.

Notable practitioners

Bernard O'Shea heads the life sciences group and has long-standing experience of the life sciences and healthcare sectors, with an especially deep understanding of commercialisation of products, licensing, distribution agreements, reimbursement issues and related regulatory regimes. A client enthuses: "In the commercial space I couldn't say enough good things about him. He brings real commercial acumen to his advice, he is fantastic." His work includes advising 4Dx, a spin-out company from Monash University, on fund-raising, licensing and regulatory issues as it seeks to develop software for use in the ultrasound analysis of the lungs.

Department profile by Norton Rose Fulbright

Department profile not yet provided by Norton Rose Fulbright. Please see their firm profile.

No Content Provided

Industries

  • {{industry.name}}

No Content Provided

Clients

  • {{client.name}}

No Content Provided

No Content Provided


DibbsBarker - Life Sciences

-

Band 3

第三等

Commentary from the Chambers Asia-Pacific guide

What the team is known for  A popular choice for mid-sized mandates. Deep understanding of the life sciences sector and offers dual-qualified practitioners who combine technical and scientific with legal expertise. Tackles work spanning corporate/M&A, IP, competition and regulatory compliance. Assists clients from all sections of the life sciences industries including start-ups and early-stage companies.

Strengths"They are client-focused, keen to get outcomes and accessible," according to clients.

Another expresses the view: "They are small to medium-sized so far, but they are growing, so I hope they don't lose that smaller-firm focus."

Work highlights  Acted for Vectus Biosystems on its IPO and listing and provided the IP advice to facilitate the listing.

Assisted OneVentures with its recent Series A investment in Clinical Genomics, a privately held biotechnology company developing innovative products for cancer diagnosis and monitoring. The OneVentures investment will assist in funding the launch of a new cancer test in the USA.

Notable practitioners

Scott Sloan is highlighted by a client "not just as an excellent lawyer" but also because "he has great subject knowledge and is an expert in IP, competition and anything to do with pharma company issues." He has some 25 years of experience in providing clients with IP and competition expertise, and his work includes acting for Alphapharm on a number of patent oppositions concerning a range of pharmaceuticals for the treatment for HIV and multiple sclerosis.

Department profile by DibbsBarker

Department profile not yet provided by DibbsBarker. Please see their firm profile.

No Content Provided

Industries

  • {{industry.name}}

No Content Provided

Clients

  • {{client.name}}

No Content Provided

No Content Provided


DLA Piper Australia - Life Sciences

-

Band 3

第三等

Commentary from the Chambers Asia-Pacific guide

What the team is known for  An impressive team with a strong focus on transactional matters and contentious and non-contentious IP. Serves a clientele comprising major pharmaceutical and healthcare companies, as well as investors. Draws on a strong global network that can provide jurisdictional expertise across multiple practice areas.

Strengths  An interviewee observes: "I am greatly impressed by the level and quality of the work undertaken, and their support."

Work highlights  Assisted SympraxInvest as fund counsel on raising the Global Cancer Research and Commercialisation Fund and creating a research collaboration platform.

Advised Intermediate Capital Group on the proposed acquisition of 100% of the shares of Everlight Radiology by funds managed or advised by Intermediate Capital and its related entities by way of a scheme of arrangement and an inter-conditional private share sale with Everlight.

Notable practitioners

Nick Tyacke, who heads the practice, focuses on IP, especially patent litigation. He continues to assist major pharma companies such as Pfizer and Wyeth on patent disputes and related regulatory issues. His work includes acting for Wyeth and Wyeth Australia in a number of separate proceedings in the Federal Court that involved eight generic companies and a parallel claim made by the Commonwealth government.

Department profile by DLA Piper Australia

Department profile not yet provided by DLA Piper Australia. Please see their firm profile.

No Content Provided

Industries

  • {{industry.name}}

No Content Provided

Clients

  • {{client.name}}

No Content Provided

No Content Provided


K&L Gates - Life Sciences

-

Band 3

第三等

Commentary from the Chambers Asia-Pacific guide

What the team is known for  An expanding group with a notably enlarged IP team. Handles complex patent litigation as part of a full-service practice, also offering corporate, competition and employment capabilities. Acts for both major life sciences corporates as well as emerging companies, many of which are involved in cutting-edge technologies. Additionally offers a global network of offices that are home to both lawyers and patent attorneys.

Strengths  Clients report a high level of satisfaction with the overall service, one remarking: "K&L Gates have generally shown a good level of familiarity with the life sciences sector, and compare very favourably in this regard with other firms."

Clients also appreciate the team's approach to billing: "Yes, I am very satisfied. All outside counsel are difficult regarding time billing and understanding the costs and making forecasts of the costs, but K&L Gates don't surprise me with bills."

Work highlights  Advised Helsinn Healthcare and Mundipharma on their strategy to enforce their patent rights in Australia, work which involved Federal Court patent litigation. The team is also handling opposition proceedings before the Patent Office in respect of the same patent that is the subject of litigation. The firm's patent attorneys also manage the client's Australian patent portfolio.

A multidisciplinary team advised the Commonwealth Scientific and Industrial Research Organisation (CSIRO) on all aspects of the structure and establishment of the CSIRO Innovation Fund, which involved corporate, investment management and tax specialisms.

Notable practitioners

Simone Mitchell is highlighted as "a quality lawyer" with a strong focus on the life sciences industry. Dr Mitchell heads the group and with her medical background she brings a well-rounded approach to patent disputes. Her busy practice includes advising Branhaven, a pioneer of animal genetics testing. She is assisting on an appeal from a decision of the Patent Office which is attracting media attention as it is one of the first patent litigation matters to be heard by the Federal Court concerning the scope and applicability of the Myriad decision in respect of method claims.

Department profile by K&L Gates

Department profile not yet provided by K&L Gates. Please see their firm profile.

No Content Provided

Industries

  • {{industry.name}}

No Content Provided

Clients

  • {{client.name}}

No Content Provided

No Content Provided


Band 1

Corrs Chambers Westgarth

From the Chambers Asia-Pacific guide

Odette Gourley is widely acknowledged for her patent litigation skills, which are combined with advisory work regarding areas such as regulations, the reimbursement system and product liability. A client declares: "She is excellent, I cannot fault her; she's responsive, and gives comfort in her advice. I have worked with a lot of firms and she is my favourite." She counts well-known life sciences corporates among her clientele and is advising a number of them on the issues surrounding the cutting-edge biosimilars industry.

^ Return to Top

Band 1

MinterEllison

From the Chambers Asia-Pacific guide

Wayne McMaster is universally admired and liked not only for his adept handling of the protection of IP assets within the life sciences sector but also for his ability to bring together all the necessary talent from within the firm. One client observes: "He really understands life sciences and pharma businesses and so the advice is pragmatic and appropriate. You get the full package -  full credit to Wayne that he has such a great team." Others make reference to his strategic approach and ability to "think ahead, see the bigger picture and boil things down into logical steps." He represented Ono Pharmaceutical and ER Squibb in a patent revocation action concerning what is thought to be the first substantive biologics patent case in Australia, which related to breakthrough PD-1 antibodies and their use in the treatment of cancer.

^ Return to Top

Band 1

Mills Oakley

From the Chambers Asia-Pacific guide

Teresa Nicoletti of Mills Oakley attracts a wealth of enthusiastic praise from both peers and clients, one explaining: "She is intelligent, insightful, there is no verbosity, she is completely direct and calls and spade a spade, and it is also nice to know with billable hours where it will go. She is powerful in her area, and I don't believe many contemporaries have her knowledge and insight." She is especially in demand for her mastery of regulatory regimes, and leads a small team that is skilled in navigating clients through patents and the pitfalls of the life sciences industries.

^ Return to Top

Band 1

Clayton Utz

From the Chambers Asia-Pacific guide

Greg Williams, who heads the healthcare and life sciences group, combines a background in biochemistry with expertise in regulatory regimes, product liability and recalls, and related IP and competition matters. He advises government agencies and pharmaceutical companies. Recently this has included advising Medicines Australia on a range of administrative law rights and competition law obligations in connection with the listing of certain formulations for the treatment of rheumatoid arthritis on the Pharmaceutical Benefits Scheme. One client characterises him as "one of the best  product liability and healthcare lawyers in Sydney," adding: "He foresees problems and has much business acumen. An absolutely key strength is that he can discuss legal problems with business sense and communicate it to management."

^ Return to Top

Band 2

Allens

From the Chambers Asia-Pacific guide

Jeremy Low, the practice head, focuses on domestic and international mergers, acquisitions and restructurings in the healthcare industries. His work includes assisting DuPont Pioneer on the restructuring and sale of its Australian agribusiness, Pioneer Australia Seeds, to New Zealand’s Philip Yates Family Holdings. A client reports that Low "provides outstanding support, legal advice and contract negotiating skills."

^ Return to Top

Band 2

Allens

From the Chambers Asia-Pacific guide

Sarah Matheson is considered by a peer to be "a fine practitioner" while a client comments: "I like interacting with her, and she is very good at managing clients, there are no surprises." She takes on patent protection and enforcement, regulatory, pricing and transactional matters for clients such as Gilead Sciences. She is acting for Gilead on a number of matters including challenging decisions of the Minister for Health in listing a new portfolio of its drugs on the Pharmaceutical Benefits Scheme incorrectly.

^ Return to Top

Band 2

Benjamin T McLaughlin

Baker McKenzie

From the Chambers Asia-Pacific guide

Benjamin McLaughlin is highlighted for "being good at leading the practice throughout APAC" and is considered "a very good guy who is extremely well connected and will go the extra mile for you." He is also considered by a client to be "a subject matter expert who adds the international flavour because he knows the other markets." He acted for IMS Health on the acquisition of 25% of healthcare data analyst NostraData and the establishment of a joint venture between IMS and NostraData.

^ Return to Top

Band 2

Norton Rose Fulbright

From the Chambers Asia-Pacific guide

Bernard O'Shea heads the life sciences group and has long-standing experience of the life sciences and healthcare sectors, with an especially deep understanding of commercialisation of products, licensing, distribution agreements, reimbursement issues and related regulatory regimes. A client enthuses: "In the commercial space I couldn't say enough good things about him. He brings real commercial acumen to his advice, he is fantastic." His work includes advising 4Dx, a spin-out company from Monash University, on fund-raising, licensing and regulatory issues as it seeks to develop software for use in the ultrasound analysis of the lungs. 

^ Return to Top

Band 3

Clayton Utz

From the Chambers Asia-Pacific guide

John Collins is well respected in the market for his "strong practice," particularly in connection with patent protection. He handles both advisory and contentious matters for an array of domestic and international pharma companies. Of late he acted for Orion Corporation in respect of patent infringement and revocation actions relating to the drug Stalevo which is used for the management of Parkinson's disease. The matter, valued at some AUD45 million, went to the Appeal Court and the case was made additionally complex as it involved a triple therapy product.

^ Return to Top

Band 3

Corrs Chambers Westgarth

From the Chambers Asia-Pacific guide

Kate Hay draws praise for being "particularly impressive as an IP litigator with a strong focus on the life sciences sector." A client elaborates that "she has good sector insight, understanding and knowledge both locally in Australia and across the Asia-Pacific region." Her broad practice includes advising Lundbeck on a range of matters including litigation with generic companies.

^ Return to Top

Band 3

MinterEllison

From the Chambers Asia-Pacific guide

James Hutton has a focus on corporate advisory work within the life sciences industries including capital raisings and fund formations. An interviewee says of him: "James is very smart, commercial and pragmatic, a really good commercial lawyer. He understands the life sciences sector – I know his work is broader but he has sector expertise." Another adds: "He is a really nice guy, easy to get on with. It's been a really pleasant working relationship." He assisted Hexima, a public unlisted drug development company, on a fully underwritten rights issue to raise capital to progress clinical trials and to develop its plant defensin technology platform.

^ Return to Top

Band 3

Herbert Smith Freehills

From the Chambers Asia-Pacific guide

Shaun McVicar is considered to be "an excellent manager of client relationships and is well respected on both pharma generic and originator-side cases." Another source confirms: "He has great rapport with clients and has great clients." He has handled a number of the highest-profile pharmaceutical cases including acting for Gilead in litigation relating to its blockbuster hepatitis C treatment which went to appeal.

^ Return to Top

Band 3

Bird & Bird

From the Chambers Asia-Pacific guide

Jane Owen of Bird & Bird is acknowledged for her IP expertise, especially patent protection and enforcement. One source comments: "She is a very experienced litigator who is comfortable in a courtroom and au fait with what is going on at the pointy end. She is very committed to her clients too." She heads up the practice and her schedule of work includes acting for both Generic Health and Alembic Pharmaceuticals in claiming compensation under an undertaking as to damages in respect of injunctions that were granted to restrain infringement of a patent which was later revoked.

^ Return to Top

Band 3

DibbsBarker

From the Chambers Asia-Pacific guide

Scott Sloan is highlighted by a client "not just as an excellent lawyer" but also because "he has great subject knowledge and is an expert in IP, competition and anything to do with pharma company issues." He has some 25 years of experience in providing clients with IP and competition expertise, and his work includes acting for Alphapharm on a number of patent oppositions concerning a range of pharmaceuticals for the treatment for HIV and multiple sclerosis.

^ Return to Top

Band 3

DLA Piper Australia

From the Chambers Asia-Pacific guide

Nick Tyacke, who heads the practice, focuses on IP, especially patent litigation. He continues to assist major pharma companies such as Pfizer and Wyeth on patent disputes and related regulatory issues. His work includes acting for Wyeth and Wyeth Australia in a number of separate proceedings in the Federal Court that involved eight generic companies and a parallel claim made by the Commonwealth government.

^ Return to Top

Band 3

Allens

From the Chambers Asia-Pacific guide

Andrew Wiseman is highly rated by a client because "he took time to understand the science and process in order to develop effective strategies to address the issues." He offers a blend of IP and transactional expertise in areas such as pharmaceuticals, medical devices and consumer and animal health. His busy practice includes assisting Merck Sharp & Dohme in successfully challenging a decision to refuse the grant of marketing authorisation in respect of the client's products for the treatment of insomnia.

^ Return to Top

Up and Coming

K&L Gates

From the Chambers Asia-Pacific guide

Simone Mitchell is highlighted as "a quality lawyer" with a strong focus on the life sciences industry. Dr Mitchell heads the group and with her medical background she brings a well-rounded approach to patent disputes. Her busy practice includes advising Branhaven, a pioneer of animal genetics testing. She is assisting on an appeal from a decision of the Patent Office which is attracting media attention as it is one of the first patent litigation matters to be heard by the Federal Court concerning the scope and applicability of the Myriad decision in respect of method claims.

^ Return to Top

Up and Coming

Baker McKenzie

From the Chambers Asia-Pacific guide

Elisabeth White leads the healthcare group and specialises in IP and regulatory matters. Her clients include a number of major pharmaceutical and medical device companies, and interviewees credit her with the ability to "instil confidence," adding: "She is clearly an expert in her area of work and a pleasure to work with." Another confirms: "She is certainly well known within the pharma sector."     

^ Return to Top